This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the following September investor conferences in New York:
Morgan Stanley Global Healthcare Conference on Tuesday, September 10 at 2:55 p.m. Eastern Time (ET) at the Grand Hyatt New York
BioCentury's 20 th Annual NewsMakers in the Biotech Industry Conference on Friday, September 27 at 10:00 a.m. ET at the Millennium Broadway Hotel
The presentations will be webcast live and available for replay from Portola's website at
www.portola.com in the
Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. Portola's wholly-owned lead compound, betrixaban, is a novel, oral, once-daily Factor Xa inhibitor in Phase 3 development for extended-duration prophylaxis of a form of thrombosis known as venous thromboembolism (VTE) in acute medically ill patients. Currently, there is no anticoagulant approved for extended-duration VTE prophylaxis in this population. Portola's second lead development candidate, andexanet alfa (PRT4445*), is a recombinant protein in Phase 2 development for which Portola retains full, worldwide commercial rights. It is designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or require emergency surgery. Portola's third product candidate, PRT2070, is an orally available kinase inhibitor that inhibits both spleen tyrosine kinase (Syk) and janus kinases (JAK). It is targeted at patients with genetically-defined hematologic cancers. Portola's fourth program, PRT2607 and other highly selective Syk inhibitors, is partnered with Biogen Idec. For more information, visit
*PRT4445 has a proposed International Nonproprietary Name (pINN) of andexanet alfa.
CONTACT: Investor Contact: